Nonsteroidal antiinf lammatory drugs (NSAIDs) can inhibit colorectal tumorigenesis and are among the few agents known to be useful for the chemoprevention of neoplasia. Here, we show that the tumor suppressive effects of NSAIDs are not likely to be related to a reduction in prostaglandins but rather are due to the elevation of the prostaglandin precursor arachidonic acid (AA). NSAID treatment of colon tumor cells results in a dramatic increase in AA that in turn stimulates the conversion of sphingomyelin to ceramide, a known mediator of apoptosis. These results have significant implications for understanding and improving colon cancer chemoprevention.
A BSTR ACT
Nonsteroidal antiinf lammatory drugs (NSAIDs) can inhibit colorectal tumorigenesis and are among the few agents known to be useful for the chemoprevention of neoplasia. Here, we show that the tumor suppressive effects of NSAIDs are not likely to be related to a reduction in prostaglandins but rather are due to the elevation of the prostaglandin precursor arachidonic acid (AA). NSAID treatment of colon tumor cells results in a dramatic increase in AA that in turn stimulates the conversion of sphingomyelin to ceramide, a known mediator of apoptosis. These results have significant implications for understanding and improving colon cancer chemoprevention.
Because common epithelial cancers have resisted most therapeutic efforts, much hope is currently placed on chemoprevention. Chemopreventive measures are especially important in patients who are at elevated risk for neoplasia caused by genetic or environmental factors. Though research on such agents is now blossoming, only a few compounds have been shown to be useful in vivo. Among these are nonsteroidal antiinflammatory drugs (NSAIDs), which are effective in reducing colon tumors in genetically susceptible humans (reviewed in ref. 1) and rodents (2) (3) (4) . Epidemiological studies have demonstrated that NSAID use in the general population is associated with a reduced risk of colon cancer death (reviewed in ref. 5) .
Further progress in this area will in part depend on understanding the mechanisms through which such chemopreventive agents exert their protective effects. It is well known that NSAIDs can inhibit cyclooxygenases (COXs) (reviewed in ref. 6) , and some studies have shown that NSAIDs can induce apoptosis (also called programmed cell death) (7) (8) (9) (10) (11) . Moreover, expression of COX2 is elevated in colorectal tumors (12) (13) (14) , and this elevation can protect intestinal epithelial cells from apoptosis (15) . However, the biochemical mechanisms through which NSAIDs and diminished COX expression alter colonic tumorigenesis are largely unknown. In this report, we describe a potential mechanism by which NSAIDs induce apoptosis in human colorectal cancer cells.
MATERIALS AND METHODS
Apoptosis Assays. Apoptosis was assessed by morphological criteria and by phosphatidylserine exposure. Morphological assessment of apoptosis was made after Hoechst 33258 staining as described (16) . Cells with fragmented nuclei were scored as apoptotic. Phosphatidylserine exposure was assessed by merocyanine staining (5 g͞ml, Sigma) as described (17) .
Arachidonic Acid (AA) Assays. AA levels were determined by release of H 3 -AA as described (18) . For representative time points, the identity of released material was confirmed to be AA by thin layer chromatography as described (19) . The increases in AA levels were further confirmed by gas chromatographic analysis of selected time points as described (20) .
Ceramide Assays. Ceramide levels were measured by using the Escherichia coli diacylglycerol kinase assay as described (21) with the following modifications. After the initial lipid extraction, phases were broken by adding 2 ml of chloroform and 2 ml of 1 M NaCl, and lipids were washed with 1 M NaCl before drying under nitrogen (22, 23) . After solubilization, samples were sonicated for 15 sec. The diacylglycerol reaction was performed for 30 min at 25°C in a 100 l reaction volume with 3.5 g of diacylglycerol kinase (Calbiochem) and 30 Ci [␥- 32 P]ATP (Dupont͞NEN, 6,000 Ci͞mmol, 1 Ci ϭ 37 GBq). After extraction of the labeled lipids, the lower chloroform phase was washed with 1% HCl before drying under nitrogen. The solvent mixture for thin layer chromatography was chloroform:acetone:methanol:acetic acid:water (10:4:3:2:1). Samples were quantitated by using a PhosphorImager (Molecular Dynamics).
Controls for Apoptosis-Induced Ceramide Increases. Three observations suggest that the ceramide increases were not the result of apoptosis. . Sphingomyelin measurements were performed by using the bacterial sphingomyelinase method as described (18) .
Neutral Sphingomyelinase Assays. Neutral sphingomyelinase activity was assayed as described (18) . After cell lysis, protein concentrations were determined by using the Bradford method (Bio-Rad), and 200 mg of cellular protein was used in each assay. Neutral sphingomyelinase activity was determined by measuring the rate of hydrolysis of 14 C-labeled sphingomyelin (Amersham). SW480 and HCT116 cell lines were treated with a SUS (50, 200, and 600 M) for 6-24 hr. None of these treatments enhanced neutral sphingomyelinase activity in cell lysates. In a typical experiment, treatment of HCT116 with 200 M of SUS resulted in a neutral sphingomyelinase activity of 90% after 6 hr and 92% after 16 hr relative to untreated controls.
RESULTS
The most extensively investigated NSAID for chemoprevention is sulindac, an agent that can reduce the size and number of colorectal tumors in familial adenomatous polyposis patients (reviewed in ref. 1) as well as in mouse models of familial adenomatous polyposis (2-4). First, we attempted to determine whether the active metabolite of sulindac, SUS, could induce the death of commonly used colorectal cancer cell lines (HCT116 and SW480) at physiologically relevant drug concentrations. SUS resulted in death of both lines in a dose-and time-dependent fashion, consistent with previous studies (7) (8) (9) (10) (11) . At concentrations of 125 M and 200 M SUS in HCT116 and SW480 cells, respectively, the majority of cells died within 48 hr (Fig. 1A) . This death appeared to be apoptotic, as it was accompanied by nuclear condensation and fragmentation and exposure of phosphatidylserine groups on the cell surface (Fig. 1B) , two hallmarks of apoptosis (26) (27) (28) .
Though the morphology of SUS-treated cells was consistent with apoptotic cell death, other cell death processes can mimic these changes. To more definitively demonstrate that SUS can actually induce apoptosis, we employed the criteria originally used to distinguish apoptosis from other death processes, namely, the requirement for macromolecular synthesis (reviewed in ref. 26) . We found that inhibition of protein synthesis by CHX (Fig.  1C) , or of RNA synthesis by actinomycin D (data not shown), could completely inhibit apoptosis at the concentrations of SUS used in Fig. 1 A. Interestingly, CHX could not inhibit SW480 cell death at higher concentrations of SUS (not shown). This finding suggests that SUS can kill cells by two mechanisms: apoptosis at relatively low concentrations and nonspecific toxic effects at higher concentrations. Such nonspecific toxicity at high concentrations of pharmaceutical compounds is not unusual (29) and may have confounded some previous studies of NSAID action. Therefore, all subsequent analyses were performed with SUS concentrations that resulted in bona fide apoptosis.
To investigate the mechanisms by which SUS induces apoptosis, we first considered the previously suggested possibility that sulindac functions through inhibiting the production of prostaglandins. To test this idea, we treated cells with both SUS and prostaglandin E 2 (PGE 2 ), the major COX product produced by colonic tumors (30) , and no inhibition of apoptosis was observed ( Fig. 2A) . Similarly, PGA 2 PGJ 2 failed to protect against NSAID-induced apoptosis and in some instances potentiated apoptosis (data not shown). This result is consistent with previous studies that suggested that prostaglandins do not affect NSAID-induced death (31, 32) . Because mouse models had demonstrated critical roles for COX2 (33) and sPLA 2 (an enzyme that produces AA) (34) (35) (36) in intestinal tumorigensis, we next considered the possibility that NSAIDs' tumor suppressive effects might be due to increased levels of the prostaglandin precursor AA resulting from inhibition of COX. To test this hypothesis, we first determined whether SUS stimulated AA accumulation. In both SW480 and HCT 116 cells, apoptosis-inducing doses of SUS increased AA by 2-to 3-fold at 24 hr and by Ϸ5-fold at 48 hr (Fig. 2 B and C) . The AA increase after SUS treatment was as great as that following treatment with mellitin, a known activator of phospholipase A 2 (data not shown). Furthermore, doses of SUS slightly lower than that required to induce apoptosis failed to induce AA release. For example, treatment of HCT116 cells with 50 M SUS did not induce apoptosis and did not increase AA levels (0.90, 1.05, and 1.14 relative to control after 8, 16, and 24 hr of treatment, respectively).
The elevated levels of AA is not simply the result of apoptosis. Treatment with 200 M SUS for 16 hr resulted in a 5.1-and 3.4-fold increase in AA in HCT116 and SW480 cells, respectively. At this time point, the majority of cells had not yet undergone apoptosis. In contrast, treatment with 100 M ceramide for 16 hr resulted in nearly complete (Ͼ90%) induction of apoptosis but only modest (1.5-and 1.9-fold) increases in AA in HCT116 and SW480 cells, respectively.
If increased AA is the true mediator of SUS activity then AA should mimic its effects. Accordingly, we found that 200 M AA was a potent inducer of apoptosis (Fig. 2D) . In contrast, 200 M behenic acid, a control fatty acid that is not a substrate for COX, had virtually no effect on apoptosis. Importantly, the effects of suboptimal SUS and AA treatment were synergistic in their ability to induce apoptosis (Fig. 2D) . These results solidly support the role of AA in SUS chemoprevention and provide strong evidence against the possibility that SUS functions predominantly by the classic prostaglandin-dependent model in which an antagonistic rather than a synergistic response would be expected for AA.
How could SUS induce apoptosis though elevation of AA levels? AA is known to stimulate neutral sphingomyelinase (18, 37) , which catalyzes the conversion of sphingomyelin to ceramide, a known inducer of apoptosis. Consistent with this possibility, we found that SUS dramatically stimulated the production of ceramide (Fig. 3 A-C) , with maximum induction at 24-48 hr (Fig.  3 F and G) . The magnitude of the ceramide increase was especially impressive (10-fold), as the induction of ceramide in other apoptotic systems is often much less. Control experiments demonstrated that these increases in ceramide were not simply the result of apoptosis (see Materials and Methods). Also, as with apoptosis and AA induction, there was a remarkable threshold in the SUS doses required for ceramide increases. At a concentra- tion of 125 M, SUS induced both cell death and ceramide in HCT116 cells (Fig. 3B and data not shown), but at 50 M, SUS induced neither. Similarly, SUS at 200 M, but not at 100 M, induced both ceramide and cell death in SW480 cells (Fig. 3C and data not shown). Finally, as with apoptosis, the induction of ceramide could be achieved by directly adding AA and strong synergism between suboptimal doses of AA and SUS was observed (Fig. 4A) . For example, doses of AA and SUS (100 M each) that had little effect on ceramide levels separately resulted in a Ͼ10-fold increase in ceramide together.
To test whether the increased ceramide was associated with evidence of augmented sphingomyelinase activity, we measured total sphingomyelin levels after SUS treatment. Sphingomyelin levels decreased by 40-50% at 48 hr after SUS treatment and, as with the other responses evaluated, suboptimal doses of SUS were inadequate to decrease sphingomyelin levels (Fig. 4 B and C) . We also measured neutral sphingomyelinase activity in lysates from the treated cells, and no differences were found (see Materials and Methods). This was consistent with the idea that it was not an increased concentration of enzyme, but rather an AA-mediated stimulation of activity, that was responsible for the decrease in sphingomyelin and the increase in ceramide. The interaction between AA and neutral sphingomyelinase would not have been predicted to be preserved during preparation of cellular lysates (18) .
If our model for sulindac action is valid, the biochemical events described above would be predicted to be induced by any inhibitor of COX, not simply SUS. To test this prediction, we treated the cells with INDO, an NSAID structurally distinct from sulindac but that also displays tumor suppressive activity (reviewed in ref. 38) . INDO was found to induce apoptosis, increase AA and ceramide concentrations, and activate sphingomyelin hydrolysis to similar degrees as SUS (Figs. 1 A and B; 2 B and C, 3 A, D-G; 4 B and C). For example, in SW480 cells, INDO induced a 3-to 4-fold increase in AA, a 6-fold increase in ceramide, and resulted in 94% of the cells undergoing apoptosis in a CHX-sensitive manner.
DISCUSSION
The results described above suggest a mechanism for the chemopreventive activity of NSAIDs ( (16) . Perturbation of lipid metabolism by pharmacological, dietary, or genetic means can partially correct the deficits. AA is generated by cytosolic and secreted phospholipase A2, which hydrolyzes plasma membrane lipids or lipids derived from the diet. AA is normally used as a substrate by the COXs to produce eicosanoids such as prostaglandins. NSAIDs inhibit the activity of the COXs, which increases the cellular pool of AA. AA stimulates neutral sphingomyelinase activity (18, 37) , which catalyzes the hydrolysis of sphingomyelin to generate ceramide. Ceramide acts as second messenger that activates the cellular apoptotic machinery. The Mom1 gene is a modifier of polyp formation in the Min mouse, a model for APC mutation-induced colon tumors. The Mom1 gene encodes a secreted phospholipase A2, an enzyme predicted to increase the level of free AA. Inactivating mutations in Mom1 predispose Min mice to developing intestinal polyps and would be expected to result in reduced levels of AA (34) (35) (36) . This in turn could result in decreased production of ceramide and therefore a relative resistance to programmed cell death and increased tumor susceptibility. The lipid compositions of diets are known to affect colon cancer risk (41, 42) . Diets rich in unsaturated fatty acids such as AA are associated with a decreased incidence of colon cancer (43) . This effect could be due to increased levels of AA and subsequent increased susceptibility to apoptosis as described above.
sulindac and INDO appear to affect tumor growth by inhibiting COX activity, causing a build-up of the COX substrate AA (Fig.  2 B-D) , and activating sphingomyelinase activity (Fig. 4 B and C) leading to production of the powerful apoptosis-inducer ceramide (Fig. 3) . This ability of SUS is not limited to colon cancer cells; primary fibroblasts and immortalized keratinocytes also increase ceramide and undergo apoptosis in response to SUS (data not shown). This is consistent with NSAIDs' ability to reduce tumor formation in a variety of tissues but does not explain the apparent greater sensitivity of tumor cells. The in vivo effect will likely depend on the local concentration of the NSAID in the incipient tumor microenvironment as well as the target cell's ''lipid biostat'' (39) . The fact that the concentration of SUS is higher in the intestines than in other organs, due to enterohepatic circulation and to the metabolic activation of sulindac to SUS by gut flora (40) , may be responsible for its particular efficacy in intestinal tumorigenesis.
The model depicted in Fig. 5 links together several apparently disparate observations. Patients genetically predisposed to colorectal tumorigenesis have a defect in a gene (adenomatous polyposis coli, or APC) that can induce apoptosis in neoplastic colorectal epithelium (16) . The efficacy of sulindac in such patients may be attributable to its functional substitution for APC in such cells. It has also been shown that modification of lipid metabolism, through inherited mutation of genes encoding a secreted phospholipase, can dramatically alter tumor incidence in mice with germline mutations of APC (34) (35) (36) , and that certain dietary lipids are correlated with colorectal cancer incidence in human populations (41, 42) . Finally, recent studies with COX-2 null mice strongly implicate inhibition of COX activity as a critical effector of NSAID chemoprevention (33) . All of these observations are consistent with the idea, summarized in Fig. 5 , that lipids, in particular ceramide and AA, play pivotal roles in protecting humans and mice from colorectal tumorigenesis through the control of apoptosis. Accordingly, manipulation of the lipids, by dietary or pharmaceutical agents, could lead to improved methods for the prevention or treatment of colorectal tumors.
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